Varicella-Zoster Virus-Derived Major Histocompatibility Complex Class I-Restricted Peptide Affinity Is a Determining Factor in the HLA Risk Profile for the Development of Postherpetic Neuralgia

ABSTRACT Postherpetic neuralgia (PHN) is the most common complication of herpes zoster and is typified by a lingering pain that can last months or years after the characteristic herpes zoster rash disappears. It is well known that there are risk factors for the development of PHN, such as its association with certain HLA alleles. In this study, previous HLA genotyping results were collected and subjected to a meta-analysis with increased statistical power. This work shows that the alleles HLA-A*33 and HLA-B*44 are significantly enriched in PHN patients, while HLA-A*02 and HLA-B*40 are significantly depleted. Prediction of the varicella-zoster virus (VZV) peptide affinity for these four HLA variants by using one in-house-developed and two existing state-of-the-art major histocompatibility complex (MHC) class I ligand prediction methods reveals that there is a great difference in their absolute and relative peptide binding repertoires. It was observed that HLA-A*02 displays a high affinity for an ∼7-fold-higher number of VZV peptides than HLA-B*44. Furthermore, after correction for HLA allele-specific limitations, the relative affinity of HLA-A*33 and HLA-B*44 for VZV peptides was found to be significantly lower than those of HLA-A*02 and HLA-B*40. In addition, HLA peptide affinity calculations indicate strong trends for VZV to avoid high-affinity peptides in some of its proteins, independent of the studied HLA allele. IMPORTANCE Varicella-zoster virus can cause two distinct diseases: chickenpox (varicella) and shingles (herpes zoster). Varicella is a common disease in young children, while herpes zoster is more frequent in older individuals. A common complication of herpes zoster is postherpetic neuralgia, a persistent and debilitating pain that can remain months up to years after the resolution of the rash. In this study, we show that the relative affinity of HLA variants associated with higher postherpetic neuralgia risk for varicella-zoster virus peptides is lower than that of variants with a lower risk. These results provide new insight into the development of postherpetic neuralgia and strongly support the hypothesis that one of its possible underlying causes is a suboptimal anti-VZV immune response due to weak HLA binding peptide affinity.

[1]  N. Jojic,et al.  HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection , 2012, Proceedings of the National Academy of Sciences.

[2]  V. Loparev,et al.  Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. , 2003, The Journal of infectious diseases.

[3]  K. Tokunaga,et al.  Association of HLA-A*3303-B*4403-DRB1*1302 haplotype, but not of TNFA promoter and NKp30 polymorphism, with postherpetic neuralgia (PHN) in the Japanese population , 2002, Genes and Immunity.

[4]  R. Cohrs,et al.  Varicella-zoster virus human ganglionic latency: a current summary , 2010, Journal of NeuroVirology.

[5]  Hiroshi Mamitsuka,et al.  Toward more accurate pan-specific MHC-peptide binding prediction: a review of current methods and tools , 2011, Briefings Bioinform..

[6]  Alessandro Sette,et al.  Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method , 2005, BMC Bioinformatics.

[7]  D. L. Crombie,et al.  The Nature of Herpes Zoster: A Long-Term Study and a New Hypothesis , 1965, Proceedings of the Royal Society of Medicine.

[8]  C. Moore,et al.  Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level , 2002, Science.

[9]  Andrew McCallum,et al.  Conditional Random Fields: Probabilistic Models for Segmenting and Labeling Sequence Data , 2001, ICML.

[10]  H. Inoko,et al.  HLA alleles are associated with postherpetic neuralgia but not with herpes zoster. , 2008, The Tokai journal of experimental and clinical medicine.

[11]  K. Schmader,et al.  Racial differences in the occurrence of herpes zoster. , 1995, The Journal of infectious diseases.

[12]  K. Schmader,et al.  Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. , 2009, The Journal of infectious diseases.

[13]  Kenji Satou,et al.  PAAQD: Predicting immunogenicity of MHC class I binding peptides using amino acid pairwise contact potentials and quantum topological molecular similarity descriptors. , 2013, Journal of immunological methods.

[14]  Alessandro Sette,et al.  The Immune Epitope Database 2.0 , 2009, Nucleic Acids Res..

[15]  V. Brusic,et al.  Evaluation of MHC class I peptide binding prediction servers: Applications for vaccine research , 2008, BMC Immunology.

[16]  T. Reinhold,et al.  Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany , 2013, The European Journal of Health Economics.

[17]  Morten Nielsen,et al.  NetCTLpan: pan-specific MHC class I pathway epitope predictions , 2010, Immunogenetics.

[18]  Kathleen Marchal,et al.  Use of structural DNA properties for the prediction of transcription-factor binding sites in Escherichia coli , 2010, Nucleic Acids Res..

[19]  A. Hughes,et al.  Conflicting selection pressures target the NS3 protein in hepatitis C virus genotypes 1a and 1b. , 2010, Virus research.

[20]  N. Zuithoff,et al.  Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: Prospective prognostic study , 2007, PAIN.

[21]  K. Dupuis,et al.  Monoclonal antibody to immediate early protein encoded by varicella-zoster virus gene 62. , 1990, Virus research.

[22]  S. Bialek,et al.  Transmission of varicella zoster virus from individuals with herpes zoster or varicella in school and day care settings. , 2012, The Journal of infectious diseases.

[23]  Hope-Simpson Re.  THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. , 1965 .

[24]  L. Bertoli,et al.  Predictors of shingles reports at diagnosis of common variable immunodeficiency and selective immunoglobulin G subclass deficiency in 212 Alabama adults , 2012, Infectious disease reports.

[25]  K. Schmader,et al.  Racial and psychosocial risk factors for herpes zoster in the elderly. , 1998, The Journal of infectious diseases.

[26]  K. Cao,et al.  Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. , 2001, Human immunology.

[27]  M. Carrington,et al.  Broadly Reactive Human CD8 T Cells that Recognize an Epitope Conserved between VZV, HSV and EBV , 2014, PLoS pathogens.

[28]  Bjoern Peters,et al.  HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and Immunogenicity , 2013, The Journal of Immunology.

[29]  K. Kawai,et al.  Systematic review of incidence and complications of herpes zoster: towards a global perspective , 2014, BMJ Open.

[30]  Paul D. Griffiths,et al.  Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[31]  K. Schmader.  Postherpetic neuralgia in immunocompetent elderly people. , 1998, Vaccine.

[32]  J. Yewdell,et al.  Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. , 2006, Immunity.

[33]  O. Lund,et al.  Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  H. Inoko,et al.  HLA-A33 and -B44 and susceptibility to postherpetic neuralgia (PHN). , 1999, Tissue antigens.

[35]  P. Peduzzi,et al.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. , 2005, The New England journal of medicine.

[36]  C. von Mering,et al.  PaxDb, a Database of Protein Abundance Averages Across All Three Domains of Life , 2012, Molecular & Cellular Proteomics.

[37]  A. Hughes,et al.  Evolution of cytotoxic T-lymphocyte epitopes in hepatitis B virus. , 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[38]  A. Hall,et al.  For Personal Use. Only Reproduce with Permission from the Lancet. Review Risk Factors for Herpes Zoster What Does Epidemiology Tell Us about Risk Factors for Herpes Zoster? , 2022 .

[39]  S. Tyring,et al.  Family history as a risk factor for herpes zoster: a case-control study. , 2008, Archives of dermatology.

[40]  O. Lund,et al.  Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy? , 2012, Expert review of vaccines.

[41]  M. Satake,et al.  The human histocompatibility leukocyte antigen (HLA) haplotype is associated with the onset of postherpetic neuralgia after herpes zoster , 2004, Pain.

[42]  P. Beutels,et al.  Influence of Frequent Infectious Exposures on General and Varicella-Zoster Virus-Specific Immune Responses in Pediatricians , 2014, Clinical and Vaccine Immunology.

[43]  P. Kinchington,et al.  Varicella zoster virus immune evasion strategies. , 2010, Current topics in microbiology and immunology.

[44]  R. Sobel,et al.  Expression of Varicella-Zoster Virus Immediate-Early Regulatory Protein IE63 in Neurons of Latently Infected Human Sensory Ganglia , 2010, Journal of Virology.

[45]  K. Schmader,et al.  The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study , 2010, Canadian Medical Association Journal.

[46]  Koenraad Van Leemput,et al.  Prediction of kinase-specific phosphorylation sites using conditional random fields , 2008, Bioinform..